[Click eStock] "Green Cross, Vaccine Growth Expected... Opportunity for Low-Price Buying"

[Asia Economy Reporter Park Jihwan] Hana Financial Investment on the 17th forecasted that Green Cross is expected to improve its performance through growth in the manufacturing vaccine sector, including influenza and chickenpox vaccines. Accordingly, it maintained a 'Buy' investment rating and a target price of 190,000 KRW.

Researcher Sun Minjeong of Hana Financial Investment explained, "In the case of Green Cross Immunoglobulin (IVIG), if the balance with albumin sales is not maintained, the cost of purchasing blood, the raw material, is excessively spent, leading to an increase in costs." However, manufacturing vaccines such as domestic and export influenza and chickenpox vaccines have a cost ratio of around 50%, resulting in good profit margins.

Researcher Sun Minjeong analyzed, "As manufacturing vaccine production increases, Green Cross's profit margin can also improve," adding, "This year, it is expected that blood product costs will be controlled through adjustment of IVIG export volumes, and manufacturing vaccines are estimated to grow by 38% compared to the previous year." Accordingly, Green Cross's operating profit is estimated to reach 68 billion KRW, a 68% increase from the previous year.

Researcher Sun emphasized, "They have secured R&D momentum such as the approval of Hunterase in China in the first half and the submission of the Biologics License Application (BLA) for IVIG in the second half," and stressed, "We recommend buying at the bottom whenever adjustments occur due to external uncertainties such as the COVID-19 pandemic."

This content was produced with the assistance of AI translation services.